1-6 of 6
Kumudu Pathiraja
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Andrew Bruce McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan M. Zaucha, Vladimir Ivanov, Vladimir Melnichenko, Heidi Mocikova, Muhit Ozcan, Caterina Patti, João Farias, Iara Zapparoli Goncalves, Olha Kuchkova, Jiri Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Katherine Ryland, Rushdia Yusuf, Wojciech Jurczak
Journal: Blood
Blood (2024) 144 (Supplement 1): 3046.
https://doi.org/10.1182/blood-2024-200323
Published: 2024
Journal Articles

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lalita Norasetthada, Joaquin Diaz, Fangfang Lv, Yuqin Song, Seung Tae Lee, Ewa Paszkiewicz-Kozik, Dipenkumar Modi, Armando Santoro, Kumudu Pathiraja, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan
Journal: Blood
Blood (2024) 144 (Supplement 1): 1738.
https://doi.org/10.1182/blood-2024-201522
Published: 2024
Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song
Journal: Blood
Blood (2023) 142 (Supplement 1): 1720.
https://doi.org/10.1182/blood-2023-186788
Published: 2023
Journal Articles

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Andrew Bruce McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan Maciej Zaucha, Vladimir Ivanov, Vladimir Melnichenko, Heidi Mocikova, Muhit Ozcan, Caterina Patti, João Farias, Iara Zapparoli Goncalves, Olha Kuchkova, Jiří Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Katherine Elizabeth Ryland, Patricia Marinello, Wojciech Jurczak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4442.
https://doi.org/10.1182/blood-2023-186800
Published: 2023
Journal Articles

Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Paolo Ghia, Lydia Scarfò, Susan Perez, Kumudu Pathiraja, Martha Derosier, Karen Small, Christine McCrary Sisk, Nigel Patton
Journal: Blood
Blood (2017) 129 (13): 1876–1878.
https://doi.org/10.1182/blood-2016-10-748210
Published: 2017
Includes: Supplemental data
Journal Articles

A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, MD PhD, Lydia Scarfo, Kumudu Pathiraja, Martha Derosier, Karen Small, Nigel Patton
Journal: Blood
Blood (2015) 126 (23): 4171.
https://doi.org/10.1182/blood.V126.23.4171.4171
Published: 2015